TherapeuticsMD Inc (TXMD) Raised to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of TherapeuticsMD Inc (NASDAQ:TXMD) from a sell rating to a hold rating in a research report released on Thursday morning.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

A number of other analysts have also recently weighed in on TXMD. Noble Financial restated a buy rating and issued a $17.50 price target on shares of TherapeuticsMD in a report on Monday, July 11th. Jefferies Group restated a buy rating on shares of TherapeuticsMD in a report on Wednesday, June 8th.

Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 6.72 on Thursday. The stock has a 50 day moving average of $6.87 and a 200-day moving average of $7.66. The stock’s market capitalization is $1.32 billion. TherapeuticsMD has a 52 week low of $5.18 and a 52 week high of $11.26.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $4.40 million for the quarter, compared to analyst estimates of $5.63 million. During the same quarter in the prior year, the company earned ($0.16) EPS. The business’s quarterly revenue was down 8.3% on a year-over-year basis. On average, equities research analysts expect that TherapeuticsMD will post ($0.43) EPS for the current year.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.